The Role of Chemotherapy in Triple Negative Breast Cancer

Volume 1 - Issue 1

Almuradova DM*

Received: May 10, 2018;   Published: May 18, 2018

DOI: 10.32474/JUNS.2018.01.000102

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Breast cancer (BC) is the most frequent tumor worldwide. Triple-negative BCs are characterized by the negative estrogen and progesterone receptors and negative HER2, and represent 12-18% of all BCs. Breast cancer (breast cancer) is the most common oncological disease in women in the Uzbekistan. Data from epidemiological studies show that TNBC is more common in young women (up to 50 years) before menopause. In addition, the likelihood of TNBC is higher in women with early menarche, the first pregnancy at an earlier age, a short period of breastfeeding, and an increased body mass index. It should be not that the prognosis for TNBC does not depend on the degree of differentiation of the tumor, the presence of lymph node metastases, the size of the tumor or the treatment performed. The aggressiveness of TNBC was also confirm by the maximum risk of recurrence during the first three years after surgical treatment with a maximum mortality within the first 5 years. TNBC is a subtype of tumors with a special character of metastasis. Based on the above, we have undertaken the present work, having set ourselves the following goal: to improve immediate and long-term results of treatment of patients with locally advanced thyroid cancer by using the most effective diagnostic methods and comprehensive treatment.

Keywords: Triple negative BC; Neoadjuvant; Adjuvant; Metastatic Chemotherapy; Paclitaxel; Docetaxel; Gemisitabin

Abbrevations: AIOM: Associazione Italiana di Oncologia Medica; ESMO: European Society for Medical Oncology; NCCN: National Comprehensive Cancer Network; q3w: Every 3 Weeks; BC: Breast Cancer

Abstract| Introduction| Materials and Methods of Research| Results| Conclusion| References|